News InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Continue Reading Previous Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology TherapeuticsNext Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors Related Stories News New AvidXchange Report Shows Finance Teams More Prepared Than in 2020—But Still Investing to Weather Uncertainty News Hitachi Energy Reduces Injuries by 95% with VelocityEHS Industrial Ergonomics Software News Ataccama brings AI to data lineage to help business users understand and trust their data News Traliant launches TikTok-inspired microlearning to boost soft skills at work News PubMatic Launches AI-Powered Live Sports Marketplace with Real-Time Game Moment Curation, FanServ Joins as Premier Partner News IP Roundtable and International Publishing Forum held at Hong Kong Book Fair today
